S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

$1.34
-0.06 (-3.93%)
(As of 02:23 PM ET)
Today's Range
$1.31
$1.43
50-Day Range
$0.83
$3.26
52-Week Range
$0.77
$14.00
Volume
72,197 shs
Average Volume
4.05 million shs
Market Capitalization
$2.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADIL stock logo

About Adial Pharmaceuticals Stock (NASDAQ:ADIL)

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

ADIL Stock Price History

ADIL Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Adial Pharmaceuticals Inc (ADIL)
MASI Apr 2024 120.000 call
MASI Apr 2024 125.000 put
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
See More Headlines
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADIL
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-12,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.17 per share

Miscellaneous

Free Float
1,422,000
Market Cap
$2.32 million
Optionable
No Data
Beta
1.52
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Cary John Claiborne MBA (Age 64)
    CEO, President & Director
    Comp: $415.08k
  • Mr. Joseph A. M. Truluck M.B.A. (Age 46)
    MBA, CFO, Treasurer & Secretary
    Comp: $279.7k
  • Mr. Tony Goodman (Age 60)
    COO & Director
    Comp: $59k
  • Dr. Bankole A. Johnson DSc (Age 64)
    FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer
    Comp: $375k
  • Mr. John R. Martin J.D.
    General Counsel
  • Mr. Alex Lugovoy
    Chief Business Officer
  • Dr. Jack W. Reich Ph.D. (Age 75)
    Head of Regulatory
    Comp: $17.01k
  • Mr. Mark H. Peikin
    Chief Strategy Officer & Chief Development Officer
  • Ms. Catherine Fratila
    Controller

ADIL Stock Analysis - Frequently Asked Questions

How have ADIL shares performed in 2024?

Adial Pharmaceuticals' stock was trading at $1.86 at the beginning of the year. Since then, ADIL stock has decreased by 27.7% and is now trading at $1.3450.
View the best growth stocks for 2024 here
.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 105,600 shares, an increase of 275.8% from the February 29th total of 28,100 shares. Based on an average trading volume of 3,820,000 shares, the short-interest ratio is currently 0.0 days. Approximately 7.0% of the shares of the stock are sold short.
View Adial Pharmaceuticals' Short Interest
.

When is Adial Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ADIL earnings forecast
.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) released its quarterly earnings results on Wednesday, August, 11th. The company reported ($6.25) EPS for the quarter, missing analysts' consensus estimates of ($5.00) by $1.25.

When did Adial Pharmaceuticals' stock split?

Shares of Adial Pharmaceuticals reverse split on the morning of Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Adial Pharmaceuticals own?
When did Adial Pharmaceuticals IPO?

Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman, Kevin Schuyler and William B Stilley III.
View institutional ownership trends
.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADIL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners